CA2191088A1 - Copolymer-1 improvements in compositions of copolymers - Google Patents

Copolymer-1 improvements in compositions of copolymers

Info

Publication number
CA2191088A1
CA2191088A1 CA002191088A CA2191088A CA2191088A1 CA 2191088 A1 CA2191088 A1 CA 2191088A1 CA 002191088 A CA002191088 A CA 002191088A CA 2191088 A CA2191088 A CA 2191088A CA 2191088 A1 CA2191088 A1 CA 2191088A1
Authority
CA
Canada
Prior art keywords
copolymer
copolymers
compositions
kilodaltons
species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002191088A
Other languages
French (fr)
Other versions
CA2191088C (en
Inventor
Eliezer Konfino
Michael Sela
Dvora Teitelbaum
Ruth Arnon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Eliezer Konfino
Michael Sela
Dvora Teitelbaum
Ruth Arnon
Yeda Research And Development Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26939072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2191088(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eliezer Konfino, Michael Sela, Dvora Teitelbaum, Ruth Arnon, Yeda Research And Development Co., Ltd. filed Critical Eliezer Konfino
Publication of CA2191088A1 publication Critical patent/CA2191088A1/en
Application granted granted Critical
Publication of CA2191088C publication Critical patent/CA2191088C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polyamides (AREA)

Abstract

The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
CA002191088A 1994-05-24 1995-05-23 Copolymer-1 improvements in compositions of copolymers Expired - Lifetime CA2191088C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24803794A 1994-05-24 1994-05-24
US34424894A 1994-11-23 1994-11-23
US08/248,037 1994-11-23
US08/344,248 1994-11-23
PCT/US1995/006551 WO1995031990A1 (en) 1994-05-24 1995-05-23 Copolymer-1 improvements in compositions of copolymers

Publications (2)

Publication Number Publication Date
CA2191088A1 true CA2191088A1 (en) 1995-11-30
CA2191088C CA2191088C (en) 2004-09-28

Family

ID=26939072

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002191088A Expired - Lifetime CA2191088C (en) 1994-05-24 1995-05-23 Copolymer-1 improvements in compositions of copolymers

Country Status (31)

Country Link
US (11) US5800808A (en)
EP (1) EP0762888B1 (en)
JP (2) JPH10500955A (en)
KR (1) KR100403750B1 (en)
CN (2) CN1174753C (en)
AT (1) ATE212857T1 (en)
AU (1) AU2602195A (en)
BR (2) BR9507758A (en)
CA (1) CA2191088C (en)
CZ (1) CZ292247B6 (en)
DE (2) DE69525340T2 (en)
DK (1) DK0762888T3 (en)
EE (1) EE03423B1 (en)
ES (1) ES2172586T3 (en)
FI (1) FI120236B (en)
GE (1) GEP20002205B (en)
HK (1) HK1008657A1 (en)
HU (1) HU223473B1 (en)
IL (2) IL113812A (en)
LU (1) LU90987I2 (en)
MD (1) MD1443G2 (en)
NL (1) NL300096I2 (en)
NO (1) NO324528B1 (en)
NZ (1) NZ287335A (en)
PL (1) PL181026B1 (en)
PT (1) PT762888E (en)
SI (1) SI0762888T1 (en)
SK (1) SK283699B6 (en)
TJ (1) TJ392B (en)
UA (1) UA62908C2 (en)
WO (1) WO1995031990A1 (en)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858980A (en) * 1990-03-30 1999-01-12 Autoimmune, Inc. Peptide fragments of myelin basic protein
US7090982B2 (en) 1991-10-22 2006-08-15 The Governors Of The University Of Alberta Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
EP1054880A1 (en) * 1998-02-13 2000-11-29 Autoimmune, Inc. TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES
WO2000005250A1 (en) 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
ES2527760T3 (en) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Treatment of Crohn's disease with copolymer 1 and polypeptides
EP1105414A2 (en) 1998-07-23 2001-06-13 President And Fellows of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
CA2794705C (en) 1998-09-25 2017-07-18 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2000020010A1 (en) * 1998-10-02 2000-04-13 Yeda Research And Development Co., Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
US7083777B1 (en) 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
ATE302020T1 (en) * 2000-01-20 2005-09-15 Yeda Res & Dev USE OF COPOLYMER 1 AND RELATED PEPTIDES AS WELL AS POLYPEPTIDES AND T CELLS TREATED THEREWITH FOR NEUROPROTECTIVE THERAPY
US7022663B2 (en) * 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
JP2003522799A (en) * 2000-02-18 2003-07-29 イエダ・リサーチ・アンド・ディベロップメント・カンパニー・リミテッド・アット・ザ・ウェイズマン・インスティテュート・オブ・サイエンス Oral, Nasal and Pulmonary Formulations of Copolymer 1
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
IL153236A0 (en) * 2000-06-05 2003-07-06 Teva Pharma The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
JP4328090B2 (en) * 2000-06-07 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド Use of Copolymer 1, Related Peptides and Polypeptides and T Cells Treated With them in Protective Therapy of Neurons
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
IL148202A0 (en) * 2000-06-20 2002-09-12 Caprion Pharmaceuticals Inc Copolymers and methods of treating prion-related diseases
IL137460A0 (en) * 2000-07-24 2001-07-24 Yeda Res & Dev Identifying antigen clusters for monitoring a global state of an immune system
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
SV2003000753A (en) 2000-12-05 2003-06-16 Brigham & Womens Hospital USE OF ZWITTERIONIC POLYSACARIDS FOR THE SPECIFIC MODULATION OF IMMUNE PROGRESS
GB2369896A (en) 2000-12-06 2002-06-12 Marconi Comm Ltd Tunable optical filter actuator
KR100442122B1 (en) * 2001-07-31 2004-07-30 한국전기연구원 Brushless generator with permanent magnet
PT1459065E (en) * 2001-12-04 2010-10-11 Teva Pharma Processes for the measurement of the potency of glatiramer acetate
IL160105A0 (en) * 2001-12-06 2004-06-20 Yeda Res & Dev Vaccine for treatment of motor neurone diseases
AU2002360696A1 (en) * 2001-12-21 2003-07-30 Ilex Oncology, Inc. Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
AU2004203772B2 (en) 2003-01-07 2009-07-16 Yeda Research And Development Co. Ltd. Eye-drop vaccine containing copolymer 1 for therapeutic immunization
PT1592384E (en) * 2003-01-21 2013-01-28 Yeda Res & Dev Cop 1 for treatment of inflammatory bowel diseases
EP1603530A1 (en) * 2003-03-04 2005-12-14 Teva Pharmaceutical Industries Limited Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
CA2520865A1 (en) 2003-03-31 2004-10-21 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
WO2005056574A2 (en) 2003-12-09 2005-06-23 Yeda Research And Development Co. Ltd. Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders
WO2005041933A1 (en) * 2003-10-31 2005-05-12 Teva Pharmaceutical Industries, Ltd. Nanoparticles for drug delivery
US20080085269A1 (en) 2003-11-12 2008-04-10 Michal Eisenbach-Schwartz Vaccine And Method For Treatment Of Neurodegenerative Diseases
AU2005211424A1 (en) * 2004-02-02 2005-08-18 Mixture Sciences, Inc. Peptide mixtures with immunomodulatory activity
KR20060125916A (en) * 2004-03-01 2006-12-06 펩팀문, 인코포레이티드 Methods and compositions for treatment of autoimmune diseases
US20070244056A1 (en) * 2004-03-03 2007-10-18 Liat Hayardeny Combination Therapy With Glatiramer Acetate and Riluzole
US20050260770A1 (en) * 2004-04-01 2005-11-24 Cohen Irun R Antigen array and diagnostic uses thereof
RU2410115C2 (en) 2004-05-07 2011-01-27 Пептиммьюн, Инк. Methods of disease treatment by means of statistical copolymers
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
RU2387453C2 (en) 2004-06-25 2010-04-27 АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК Compositions and methods of treating neurological disturbances
DK1797109T3 (en) * 2004-09-09 2016-04-11 Yeda Res & Dev MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
EP2177528B1 (en) * 2004-09-09 2011-12-07 Teva Pharmaceutical Industries Ltd. Process for the preparation of mixtures of trifluoroacetyl glatiramer acetate using purified hydrobromic acid
US8324641B2 (en) * 2007-06-29 2012-12-04 Ledengin, Inc. Matrix material including an embedded dispersion of beads for a light-emitting device
DE602005016292D1 (en) * 2004-10-29 2009-10-08 Sandoz Ag PROCESS FOR THE PRODUCTION OF GLATIRAMER
WO2006057003A2 (en) * 2004-11-29 2006-06-01 Yeda Research And Development Co. Ltd. Induction of neurogenesis and stem cell therapy in combination with copolymer 1
EP1838326A4 (en) * 2005-02-02 2009-09-30 Teva Pharma Process for producing polypeptide mixtures using hydrogenolysis
PT1848415E (en) * 2005-02-17 2013-06-27 Teva Pharma Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
EP1891233A4 (en) * 2005-04-25 2010-03-24 Yeda Res & Dev Markers associated with the therapeutic efficacy of glatiramer acetate
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
AU2007238595A1 (en) 2006-04-13 2007-10-25 Peptimmune, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
WO2007127977A2 (en) 2006-04-28 2007-11-08 Momenta Pharmaceuticals, Inc. Methods of evaluating peptide mixtures
KR100831796B1 (en) * 2006-05-29 2008-05-28 엘지전자 주식회사 An image display device for having time shift function and method for playing of the same
JP5412280B2 (en) 2006-06-28 2014-02-12 イエダ リサーチ アンド デベロップメント カンパニー リミテッド Treatment of age-related macular degeneration
ATE452140T1 (en) * 2006-07-05 2010-01-15 Momenta Pharmaceuticals Inc IMPROVED PROCESS FOR PRODUCING COPOLYMER-1
CN101743470A (en) 2007-06-21 2010-06-16 动量制药公司 copolymer assay
US20090029766A1 (en) * 2007-07-26 2009-01-29 Lutnick Howard W Amusement gaming access and authorization point
CA2705046C (en) * 2007-07-31 2015-03-03 Natco Pharma Limited Process for the preparation glatiramer acetate (copolymer-1)
KR20170075026A (en) 2007-10-16 2017-06-30 펩팀문, 인코포레이티드 Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
WO2009062132A2 (en) 2007-11-09 2009-05-14 California Institute Of Technology Immunomodulating compounds and related compositions and methods
CA2702437C (en) * 2007-11-28 2013-06-25 Teva Pharmaceutical Industries Ltd. Method of delaying the onset of clinically definite multiple sclerosis
ES2449865T5 (en) * 2008-04-16 2022-11-18 Momenta Pharmaceuticals Inc Analysis of compositions of amino acid copolymers
PL2307448T3 (en) * 2008-08-07 2015-10-30 Sigma Aldrich Co Llc Preparation of low molecular weight polylysine and polyornithine in high yield
WO2010017292A1 (en) * 2008-08-07 2010-02-11 Scinopharm Taiwan, Ltd. Synthesis of glatiramer acetate
AR074881A1 (en) 2008-12-24 2011-02-16 Synthon Bv A PROCESS TO PURIFY A MIXTURE OF POLYMERS
US8859489B2 (en) * 2009-04-03 2014-10-14 Momenta Pharmaceuticals, Inc. Water-mediated control of depolymerization step of glatiramer acetate synthesis
AU2009347384B2 (en) * 2009-06-04 2014-10-23 Council Of Scientific & Industrial Research A process for the preparation of copolymer - 1 (Cop-I), composed of L-alanine, L-lysine, L-glutamic acid and L-tyrosine-drug for the treatment of multiple sclerosis
ES2383347T3 (en) 2009-07-15 2012-06-20 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and administration procedures
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
US8691790B2 (en) * 2009-07-27 2014-04-08 James Layne Boucher Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
DE202010018377U1 (en) 2009-08-20 2016-02-25 Yeda Research And Development Co., Ltd. LOW-FREQUENT THERAPY WITH GLATIRAMERACETATE
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
ES2699692T3 (en) 2010-01-04 2019-02-12 Mapi Pharma Ltd Deposit system comprising glatiramer acetate
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US20130035390A1 (en) 2010-01-13 2013-02-07 Ramot At Tel-Aviv University Ltd. Treatment of multiple sclerosis
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
EP2555753B1 (en) 2010-04-07 2018-08-01 California Institute of Technology Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
EP2563804A4 (en) * 2010-04-27 2014-09-17 Reddys Lab Ltd Dr Preparation of polypeptides and salts thereof
EP2571982A4 (en) 2010-05-20 2014-01-01 California Inst Of Techn Antigen specific tregs and related compositions, methods and systems
US9109006B2 (en) * 2010-07-29 2015-08-18 Santhanakrishnan Srinivasan Glatiramer acetate molecular weight markers
EA025780B1 (en) 2010-10-11 2017-01-30 Тева Фармасьютикал Индастриз Лтд. Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
US9029507B2 (en) 2011-02-14 2015-05-12 Usv Limited Copolymer-1, process for preparation and analytical methods thereof
EP2699317B1 (en) * 2011-04-21 2016-08-10 Mapi Pharma Limited Random pentapolymer for treatment of autoimmune diseases
US20140348861A1 (en) 2011-05-05 2014-11-27 National Institute Of Immunology Synthetic peptides and random copolymers for the treatment of autoimmune disorders
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
WO2013009864A1 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Structure assessment of heterogeneous polypeptide mixtures
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
KR20140101730A (en) 2011-10-10 2014-08-20 테바 파마슈티컬 인더스트리즈 리미티드 Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
WO2013139728A1 (en) 2012-03-19 2013-09-26 Synthon Bv Glatiramer acetate human monocyte cell-based potency assay
EP2642290A1 (en) 2012-03-19 2013-09-25 Synthon BV Glatiramer acetate human monocytic cell line-based potency assay
US20140045740A1 (en) * 2012-08-13 2014-02-13 Momenta Pharmaceuticals, Inc. Analysis of glatiramer acetate
US9617596B2 (en) 2012-10-10 2017-04-11 Teva Pharmaceutical Industries, Ltd. Biomarkers predictive for clinical response for glatiramer acetate
WO2014060942A2 (en) * 2012-10-20 2014-04-24 Mahesh Kandula Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
WO2014128079A1 (en) 2013-02-19 2014-08-28 Synthon B.V. Glatiramer acetate multidose formulation
PT2774640E (en) 2013-03-08 2015-02-09 Teva Pharma Re-useable injector device for syringe
PT2774639E (en) 2013-03-08 2015-01-13 Teva Pharma Re-useable injector device for syringe
JP6553018B2 (en) 2013-03-14 2019-07-31 マイラン・インコーポレイテッドＭｙｌａｎ Ｉｎｃ． Acetic acid glatiramer response biomarker mRNA potency assay
WO2014173463A1 (en) 2013-04-26 2014-10-30 Synthon Bv Glatiramer acetate human monocytic cell line-based potency assay
EP2994161B1 (en) 2013-05-10 2020-10-28 California Institute of Technology Probiotic prevention and treatment of colon cancer
CN103265624B (en) * 2013-05-27 2015-04-22 成都圣诺生物制药有限公司 Method for preparing copaxone
CN104371012A (en) * 2013-08-12 2015-02-25 深圳翰宇药业股份有限公司 Synthesis method of glatiramer acetate
UY35790A (en) 2013-10-21 2015-05-29 Teva Pharma GENETIC MARKERS THAT PREACH THE RESPONSE TO THE GLATIRAMER ACETATE
EP3060684A4 (en) 2013-10-24 2017-06-07 Mylan Inc. Human t cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
US10545144B2 (en) 2013-12-31 2020-01-28 Yeda Research And Development Co., Ltd. Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
JP6903432B2 (en) 2014-03-12 2021-07-14 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド Decreasing the level or activity of systemic regulatory T cells to treat CNS diseases and injuries
CN104844697B (en) 2014-09-26 2018-10-23 深圳翰宇药业股份有限公司 The preparation method of acetic acid copaxone
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN107533058A (en) 2015-03-01 2018-01-02 免疫阵列有限公司 Use albumen, peptide and oligonucleotides diagnostic antigen systemic loupus erythematosus
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
CN108135167B (en) 2015-08-19 2021-07-09 哈佛学院院长及董事 Lipidated PSA compositions and methods
ES2744179T3 (en) 2015-09-24 2020-02-24 Chemi Spa Analysis of the molecular weight distribution of complex polypeptide mixtures
ES2707500T3 (en) 2015-11-23 2019-04-03 Chemi Spa Analysis by RP-HPLC of mixtures of complex polypeptides
CN107522774B (en) * 2016-06-22 2021-07-02 深圳翰宇药业股份有限公司 Real-time control method for piperidine residual quantity in glatiramer acetate preparation process
WO2018002930A1 (en) 2016-06-30 2018-01-04 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
CA3030974A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
MX2019001999A (en) 2016-08-28 2019-08-29 Mapi Pharma Ltd Process for preparing microparticles containing glatiramer acetate.
HRP20230738T1 (en) 2016-08-31 2023-10-27 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
WO2018178973A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
JP7000458B2 (en) 2017-05-15 2022-02-10 ステム セル メディスン リミテッド Treatment of multiple sclerosis with long-acting glatiramer and adipose-derived stem cells
JP2020519645A (en) 2017-05-15 2020-07-02 ステム セル メディスン リミテッド Treatment of multiple sclerosis with adipose tissue-derived stem cells
EP3765034A1 (en) 2018-03-12 2021-01-20 Yeda Research and Development Co. Ltd Treatment of a heart disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US4444760A (en) 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
JPS6053535A (en) 1983-09-02 1985-03-27 Nitto Boseki Co Ltd Production of regular polyaminoacid resin
SU1182051A1 (en) 1984-04-28 1985-09-30 Таджикский государственный университет им.В.И.Ленина Polytripeptides possessing oenantic selectivity in reactions of hydrolysis of carbobenzoxy-d-1 alanine n-nitrophenyl esters
DE3684333D1 (en) 1985-06-18 1992-04-16 Univ Emory BIOLOGICALLY EFFECTIVE COPOLYMERS.
DD257174A3 (en) 1985-12-20 1988-06-08 Ve Forschungszentrum Biotechno PROCESS FOR PREPARING THE PEPTIDES Z ALA ALA LON P NITRANILIDE OR Z ASP ASP PHE OME WITH METALOPROTEASE
SU1469826A1 (en) 1986-05-30 1995-11-20 Институт Высокомолекулярных Соединений Ан Ссср Copolymer of l-lysine and l-glutamic acid containing side groups and showing prolonged hypotensive activity and compensatory effect at hemorrhagic shock, and a method of its preparing
US4828706A (en) 1988-03-07 1989-05-09 Spectrum Medical Industries Process for performing a dialysis operation
US4908404A (en) * 1988-08-22 1990-03-13 Biopolymers, Inc. Synthetic amino acid-and/or peptide-containing graft copolymers
DE8900366U1 (en) * 1989-01-13 1989-08-03 Indag Gesellschaft Fuer Industriebedarf Mbh, 6904 Eppelheim, De
CA2009996A1 (en) * 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
SU1690368A1 (en) 1989-07-20 1995-08-20 Институт Высокомолекулярных Соединений Ан Ссср Statistic copolymers as low toxic compounds having prolonged hypotensive action and method for their production
DE3930733A1 (en) 1989-09-14 1991-03-28 Roehm Gmbh METHOD FOR PRODUCING A COMPLEX MEDICINAL PRODUCT
JP2653255B2 (en) * 1990-02-13 1997-09-17 武田薬品工業株式会社 Long-term sustained release microcapsules
WO1993010231A1 (en) * 1991-11-12 1993-05-27 E.I. Du Pont De Nemours And Company Collagen-like polypeptides
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
JP2001524011A (en) 1997-05-06 2001-11-27 クワンタ・ビジョン Tissue analyzer
ATE302020T1 (en) * 2000-01-20 2005-09-15 Yeda Res & Dev USE OF COPOLYMER 1 AND RELATED PEPTIDES AS WELL AS POLYPEPTIDES AND T CELLS TREATED THEREWITH FOR NEUROPROTECTIVE THERAPY
US6936539B2 (en) * 2003-09-24 2005-08-30 Micron Technology, Inc. Antireflective coating for use during the manufacture of a semiconductor device

Also Published As

Publication number Publication date
EP0762888B1 (en) 2002-02-06
NO324528B1 (en) 2007-11-12
EP0762888A4 (en) 1997-04-16
PL181026B1 (en) 2001-05-31
US20070117757A1 (en) 2007-05-24
US6939539B2 (en) 2005-09-06
PL317331A1 (en) 1997-04-01
US20030064914A1 (en) 2003-04-03
ES2172586T3 (en) 2002-10-01
KR970703154A (en) 1997-07-03
CZ341096A3 (en) 1997-06-11
CN1626238A (en) 2005-06-15
BRPI9507758B1 (en) 2021-03-16
DE69525340T2 (en) 2002-09-19
UA62908C2 (en) 2004-01-15
NZ287335A (en) 1999-02-25
DE69525340D1 (en) 2002-03-21
HK1008657A1 (en) 1999-05-14
NL300096I2 (en) 2003-02-03
GEP20002205B (en) 2000-08-25
US6362161B1 (en) 2002-03-26
AU2602195A (en) 1995-12-18
NO964976L (en) 1997-01-23
CN1152874A (en) 1997-06-25
CN1310673C (en) 2007-04-18
MD1443F1 (en) 2000-04-30
HU223473B1 (en) 2004-07-28
KR100403750B1 (en) 2006-02-13
SK149396A3 (en) 1997-08-06
ATE212857T1 (en) 2002-02-15
EP0762888A1 (en) 1997-03-19
EE03423B1 (en) 2001-06-15
US20040106554A1 (en) 2004-06-03
US5800808A (en) 1998-09-01
FI120236B (en) 2009-08-14
US7199098B2 (en) 2007-04-03
NO964976D0 (en) 1996-11-22
US20050171286A1 (en) 2005-08-04
US6620847B2 (en) 2003-09-16
US7625861B2 (en) 2009-12-01
HUT75672A (en) 1997-05-28
EE9600170A (en) 1997-06-16
FI964600A (en) 1996-12-05
US6048898A (en) 2000-04-11
SI0762888T1 (en) 2002-08-31
JP3715600B2 (en) 2005-11-09
CN1174753C (en) 2004-11-10
PT762888E (en) 2002-07-31
NL300096I1 (en) 2002-10-01
US20120077754A1 (en) 2012-03-29
US8367605B2 (en) 2013-02-05
CA2191088C (en) 2004-09-28
DE10299030I1 (en) 2003-01-23
DK0762888T3 (en) 2002-05-27
LU90987I2 (en) 2003-02-25
IL113812A0 (en) 1995-08-31
HU9603243D0 (en) 1997-01-28
JP2003105000A (en) 2003-04-09
BR9507758A (en) 1997-09-23
US6342476B1 (en) 2002-01-29
US6054430A (en) 2000-04-25
CZ292247B6 (en) 2003-08-13
FI964600A0 (en) 1996-11-15
SK283699B6 (en) 2003-12-02
MD1443G2 (en) 2000-11-30
IL133890A0 (en) 2001-04-30
WO1995031990A1 (en) 1995-11-30
TJ392B (en) 2004-10-13
IL113812A (en) 2000-06-29
JPH10500955A (en) 1998-01-27
US5981589A (en) 1999-11-09

Similar Documents

Publication Publication Date Title
CA2191088A1 (en) Copolymer-1 improvements in compositions of copolymers
CA2099377A1 (en) Superior stain resistant compositions
NZ333993A (en) Compositions of EPO having a single covalently bound N-terminal water-soluble polymer
EP1056469A4 (en) Novel peptide copolymer compositions
EP1262527A3 (en) Antistatic polymer compositions
CA2184551A1 (en) Iron dextran formulations
WO1999017711A3 (en) Autophobic hairspray compositions
SG38904A1 (en) High performance polymer compositions
AU2981299A (en) Nylon 6 or 66 based compositions and films formed therefrom
AU5117790A (en) Improved clear organosiloxane compositions
CA2211568A1 (en) Organosilicon compounds containing amino groups, their preparation and their use
AU3743797A (en) Polysulfone copolymer compositions
IL95773A0 (en) Polymer compositions comprising graft copolymer impact modifier
ZA954220B (en) Copolymer-1: compositions of copolymers
FR2656321B1 (en) COMPOSITIONS COMPRISING ETHYLENE COPOLYMERS.
EP0647703A3 (en) Polymer compositions of improved compatibility in oil.
AU586551B2 (en) High impact nylon block copolymer compositions
CA2347809A1 (en) Fabric care compositions having reduced fabric abrasion
CA2305666A1 (en) Resin composition of improved elongation
AU4608289A (en) Toughened polyamide compositions having improved properties
CA2248008A1 (en) Bar composition comprising copolymer mildness actives

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20150525